Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients.

1591Background: Hereditary predisposition is estimated to account for 10% of all PC cases. Identification of pathogenic germline mutationscan inform not only screening recommendations for family members but also, increasingly, treatment selection for pts. However, referral patterns and clinical workflow for germlinetesting in this disease differ significantly by institution, and many pts may not undergo recommended testing for a variety of reasons. Methods: We performed a retrospective review of all pts diagnosed w/ PC referred to our University of California, San Francisco Clinical Genetics programover a 3-yr period (1/2015 – 10/2017). Medical records were reviewed for demographic, medical/family history, and disease-specific data as well as genetic testing results. If testing did not occur, the reason was documented. Results were categorized as negative, variants of unknown significance (VUS), or established pathogenic mutations. Descriptive statistics included means with standard deviations (SD); as...